Does the media prefer BMRN or ALNY?

In the previous week, Alnylam Pharmaceuticals had 6 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 17 mentions for Alnylam Pharmaceuticals and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.14 beat Alnylam Pharmaceuticals' score of 0.94 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMRN or BIIB?

In the previous week, Biogen had 11 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 22 mentions for Biogen and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.14 beat Biogen's score of 0.71 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 11 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer BMRN or INCY?

In the previous week, Incyte had 18 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 29 mentions for Incyte and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.14 beat Incyte's score of 1.04 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 17 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or BMRN?

In the previous week, United Therapeutics had 3 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 14 mentions for United Therapeutics and 11 mentions for BioMarin Pharmaceutical. United Therapeutics' average media sentiment score of 1.53 beat BioMarin Pharmaceutical's score of 1.14 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioMarin Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMRN or NBIX?

In the previous week, Neurocrine Biosciences had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 16 mentions for Neurocrine Biosciences and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.14 beat Neurocrine Biosciences' score of 1.12 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioMarin Pharmaceutical (BMRN) Competitors

$59.21 +0.10 (+0.17%)

Closing price 04:00 PM Eastern

Extended Trading

$58.00 -1.21 (-2.04%)

As of 06:20 PM Eastern

Compare

BMRN vs. ALNY, BIIB, INCY, UTHR, and NBIX

Should you buy BioMarin Pharmaceutical stock or one of its competitors? MarketBeat compares BioMarin Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has a net margin of 11.72% compared to BioMarin Pharmaceutical's net margin of 8.29%. Alnylam Pharmaceuticals' return on equity of 85.76% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	8.29%	6.50%	5.07%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

BioMarin Pharmaceutical has higher earnings, but lower revenue than Alnylam Pharmaceuticals. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.55	$348.90M	$1.37	43.22
Alnylam Pharmaceuticals	$3.71B	9.76	$313.75M	$3.66	74.14

In the previous week, Alnylam Pharmaceuticals had 6 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 17 mentions for Alnylam Pharmaceuticals and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.14 beat Alnylam Pharmaceuticals' score of 0.94 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical currently has a consensus target price of $88.26, indicating a potential upside of 49.06%. Alnylam Pharmaceuticals has a consensus target price of $455.31, indicating a potential upside of 67.78%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats BioMarin Pharmaceutical on 14 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Biogen?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.55	$348.90M	$1.37	43.22
Biogen	$9.89B	3.03	$1.29B	$9.32	21.80

Biogen has a net margin of 13.81% compared to BioMarin Pharmaceutical's net margin of 8.29%. Biogen's return on equity of 12.83% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	8.29%	6.50%	5.07%
Biogen	13.81%	12.83%	8.01%

BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Biogen has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

In the previous week, Biogen had 11 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 22 mentions for Biogen and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.14 beat Biogen's score of 0.71 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	11 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

BioMarin Pharmaceutical currently has a consensus price target of $88.26, suggesting a potential upside of 49.06%. Biogen has a consensus price target of $220.57, suggesting a potential upside of 8.57%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71
Biogen	2 Sell rating(s)	12 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.53

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

BioMarin Pharmaceutical and Biogen tied by winning 8 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Incyte?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Incyte had 18 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 29 mentions for Incyte and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.14 beat Incyte's score of 1.04 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	17 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Incyte has higher revenue and earnings than BioMarin Pharmaceutical. Incyte is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.55	$348.90M	$1.37	43.22
Incyte	$5.14B	4.56	$1.29B	$7.08	16.58

BioMarin Pharmaceutical presently has a consensus price target of $88.26, suggesting a potential upside of 49.06%. Incyte has a consensus price target of $109.95, suggesting a potential downside of 6.34%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36

Incyte has a net margin of 26.71% compared to BioMarin Pharmaceutical's net margin of 8.29%. Incyte's return on equity of 26.66% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	8.29%	6.50%	5.07%
Incyte	26.71%	26.66%	19.77%

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Incyte beats BioMarin Pharmaceutical on 10 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

United Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to BioMarin Pharmaceutical's net margin of 8.29%. United Therapeutics' return on equity of 19.24% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
BioMarin Pharmaceutical	8.29%	6.50%	5.07%

United Therapeutics presently has a consensus price target of $644.82, suggesting a potential upside of 20.34%. BioMarin Pharmaceutical has a consensus price target of $88.26, suggesting a potential upside of 49.06%. Given BioMarin Pharmaceutical's higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, United Therapeutics had 3 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 14 mentions for United Therapeutics and 11 mentions for BioMarin Pharmaceutical. United Therapeutics' average media sentiment score of 1.53 beat BioMarin Pharmaceutical's score of 1.14 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioMarin Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has higher earnings, but lower revenue than BioMarin Pharmaceutical. United Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.17B	7.18	$1.33B	$27.09	19.78
BioMarin Pharmaceutical	$3.22B	3.55	$348.90M	$1.37	43.22

Summary

United Therapeutics beats BioMarin Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Neurocrine Biosciences?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

BioMarin Pharmaceutical presently has a consensus target price of $88.26, indicating a potential upside of 49.06%. Neurocrine Biosciences has a consensus target price of $194.05, indicating a potential upside of 8.38%. Given BioMarin Pharmaceutical's higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Neurocrine Biosciences has a net margin of 21.55% compared to BioMarin Pharmaceutical's net margin of 8.29%. Neurocrine Biosciences' return on equity of 19.79% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	8.29%	6.50%	5.07%
Neurocrine Biosciences	21.55%	19.79%	13.82%

In the previous week, Neurocrine Biosciences had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 16 mentions for Neurocrine Biosciences and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.14 beat Neurocrine Biosciences' score of 1.12 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has lower revenue, but higher earnings than BioMarin Pharmaceutical. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.55	$348.90M	$1.37	43.22
Neurocrine Biosciences	$2.86B	6.29	$478.60M	$6.49	27.59

Summary

Neurocrine Biosciences beats BioMarin Pharmaceutical on 12 of the 17 factors compared between the two stocks.

Get BioMarin Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRN vs. The Competition

Export

Metric	BioMarin Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.44B	$3.65B	$6.81B	$12.41B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	43.22	20.79	27.00	24.19
Price / Sales	3.55	313.75	516.15	92.44
Price / Cash	20.89	60.31	26.68	47.25
Price / Book	1.87	8.17	10.67	6.26
Net Income	$348.90M	$23.81M	$3.60B	$331.76M
7 Day Performance	0.97%	-1.16%	-0.37%	-1.10%
1 Month Performance	8.26%	2.59%	1.80%	-1.29%
1 Year Performance	4.69%	45.43%	25.50%	18.84%

BioMarin Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRN BioMarin Pharmaceutical	4.4414 of 5 stars	$59.21 +0.2%	$88.26 +49.1%	+3.2%	$11.44B	$3.22B	43.22	3,221	News Coverage Positive News
ALNY Alnylam Pharmaceuticals	4.4184 of 5 stars	$271.69 -4.0%	$455.31 +67.6%	-14.9%	$36.21B	$3.71B	74.11	2,770
BIIB Biogen	3.6453 of 5 stars	$205.96 -1.4%	$220.04 +6.8%	+60.0%	$30.40B	$9.89B	22.09	7,500	Analyst Forecast
INCY Incyte	2.8944 of 5 stars	$116.90 +0.2%	$109.95 -5.9%	+70.4%	$23.36B	$5.14B	16.51	2,844	Trending News Upcoming Earnings Analyst Forecast
UTHR United Therapeutics	4.6063 of 5 stars	$536.64 +1.4%	$644.82 +20.2%	+81.3%	$22.77B	$3.18B	19.80	1,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Summary

How does BioMarin Pharmaceutical compare to Incyte?

Summary

How does BioMarin Pharmaceutical compare to United Therapeutics?

Summary

How does BioMarin Pharmaceutical compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Do institutionals & insiders have more ownership in BMRN or ALNY?

Is BMRN or ALNY more profitable?

Which has preferable earnings & valuation, BMRN or ALNY?

Does the media prefer BMRN or ALNY?

Do analysts recommend BMRN or ALNY?

Which has more risk & volatility, BMRN or ALNY?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Which has stronger earnings & valuation, BMRN or BIIB?

Is BMRN or BIIB more profitable?

Which has more risk & volatility, BMRN or BIIB?

Does the media refer more to BMRN or BIIB?

Do analysts recommend BMRN or BIIB?

Do institutionals & insiders hold more shares of BMRN or BIIB?

Summary

How does BioMarin Pharmaceutical compare to Incyte?

Does the media prefer BMRN or INCY?

Which has more volatility and risk, BMRN or INCY?

Which has preferable earnings and valuation, BMRN or INCY?

Do analysts prefer BMRN or INCY?

Is BMRN or INCY more profitable?

Do insiders and institutionals hold more shares of BMRN or INCY?

Summary

How does BioMarin Pharmaceutical compare to United Therapeutics?

Do institutionals and insiders believe in UTHR or BMRN?

Which has more volatility and risk, UTHR or BMRN?

Is UTHR or BMRN more profitable?

Do analysts rate UTHR or BMRN?

Does the media favor UTHR or BMRN?

Which has higher valuation and earnings, UTHR or BMRN?

Summary

How does BioMarin Pharmaceutical compare to Neurocrine Biosciences?

Do analysts recommend BMRN or NBIX?

Do insiders and institutionals believe in BMRN or NBIX?

Which has more volatility and risk, BMRN or NBIX?

Is BMRN or NBIX more profitable?

Does the media refer more to BMRN or NBIX?

Which has better earnings and valuation, BMRN or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools